Previous Close | 1.3000 |
Open | 1.1900 |
Bid | 1.1800 x 0 |
Ask | 1.2800 x 0 |
Day's Range | 1.1900 - 1.2500 |
52 Week Range | 0.8000 - 1.5000 |
Volume | |
Avg. Volume | 4,759 |
Market Cap | 12.814M |
Beta (5Y Monthly) | 0.87 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.6410 |
Earnings Date | Apr 25, 2023 - May 01, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended September 30, 2022.
Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the Q3 Financial Results on a Conference Call on November 25, 2022 at 8:30 am Eastern Time. The Q3 Financials will be filed after closing the day before.
This release is being issued in connection with the filing of an early warning report (the "Early Warning Report") pursuant to the requirements of National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues regarding the change in the ownership and control of common shares (the "Common Shares") of Medicure Inc. (the "Issuer") by Dr. Albert D. Friesen ("Dr. Friesen"). The Issuer's head office address and Dr. Friesen's business address is 2-1250 Wav